Table 1.
Baseline characteristics of the total population cohort
| Reference population (n=4,234,793) | Psoriasis (n=87,161) | |
|---|---|---|
|
| ||
| Age, mean (SD) | 48.6 (18.0) | 53.8 (16.3) |
| Sex, n (%) | ||
| Women | 2,148,653 (50.7) | 45,809 (52.6) |
| Men | 2,086,140 (49.3) | 41,352 (47.4) |
| Duration of psoriasis | ||
| Mean (SD) | NA | 7.8 (5.2) |
| Median (IQR) | NA | 7.7 (3.9–11.2) |
| Age at onset of psoriasis, mean (SD) | NA | 46.0 (16.6) |
| Socioeconomic status, mean (SD) | 2.0 (1.3) | 2.2 (1.3) |
| Hospitalized (inpatient) for psoriasis, n (%) | NA | 4,975 (5.7) |
| Smoking, n (%) | 337,551 (8.0) | 10,459 (12.0) |
| Comorbidity, n (%) | ||
| Alcohol abuse | 58,671 (1.4) | 1,672 (1.9) |
| Cardiovascular disease | 364,023 (8.6) | 11,737 (13.5) |
| Diabetes | 151,043 (3.6) | 5,376 (6.2) |
| Hypertension | 506,836 (12.0) | 15,908 (18.3) |
| Psoriatic arthritis | 2,515 (0.1) | 5,742 (6.6) |
| Treatment*, n (%) | ||
| Biologics | 2,760 (0.1) | 663 (0.8) |
| Cholesterol lowering drugs | 384,425 (9.1) | 12,436 (14.3) |
| Cyclosporine | 985 (0.0) | 193 (0.2) |
| Methotrexate | 13,971 (0.3) | 3,189 (3.7) |
| PUVA/UVB phototherapy | 346 (0.0) | 264 (0.3) |
| Retinoids (acitretin/etretinate) | 395 (0.0) | 553 (0.6) |
| Topical vitamin D analogues | NA | 12,621 (14.5) |
IQR, interquartile range; NA, not applicable; PUVA, psoralen plus ultraviolet A; SD, standard deviation; UVB, ultraviolet B
*
Within the last 6 months